MERCK SHARP & DOHME CORP - 
Ranking results:
Past rankings:
| 2020 | |
|---|---|
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Total Number of Projects: | > 1000 |
| 2019 | |
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Total Number of Projects: | 900-1000 |
| 2018 | |
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Total Number of Projects: | > 1000 |
| Networking Rank (Reputation): | > 1000 |
Ranking timeline:
Project Participation Performance(2018-01-01 - 2024-12-31 ):
Total Project Funding:
Funding per Partner:
Projects:
Leadership:
Total number of projects: 7
As coordinator: 0
As participant: 7
Sole participant: 0
Coordinator / Participant Ratio: 0*
Summary:
| Total project funding [€]: | Projects [No]: | |||||
|---|---|---|---|---|---|---|
| Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
| 2020 | 0 | 12.840.693 | 0 | 2 | ||
| 2019 | 0 | 35.830.196 | 0 | 4 | ||
| 2018 | 0 | 4.498.931 | 0 | 1 | ||
Networking:
Partners:
Constancy:
Total number of partners: 182
Partner loyalty:
Frequent Partner: (> 2 projects): 37
Rare Partner: 145
Frequent / Rare Partner Ratio: 0.26
Project overview:
| Start date | Project | acronym | role | funding | partners |
|---|---|---|---|---|---|
| 2020-09-01 | Prioritisation and Risk Evaluation of Medicines in the EnviRonment | PREMIER | participant | 4.550.000 | 25 |
| 2020-01-01 | PharmaLedger | PharmaLedger | participant | 8.290.694 | 30 |
| 2019-12-01 | Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies | imSAVAR | participant | 10.999.316 | 28 |
| 2019-03-01 | Neurotoxicity De-Risking in Preclinical Drug Discovery | NeuroDeRisk | participant | 5.331.000 | 18 |
| 2019-02-01 | Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease | TransBioLine | participant | 13.999.998 | 29 |
| 2019-01-01 | Vaccines and Infectious Diseases in the Ageing PopuLation | VITAL | participant | 5.499.882 | 24 |
| 2018-03-01 | Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes. | PARADIGM | participant | 4.498.931 | 35 |